Due to the rising obesity epidemic, the market for a safe and effective weight loss drug is extremely compelling. A successfully commercialized weight loss drug that proves safe and effective long-term has the potential to reach blockbuster status and generate sales in the billions of dollars, while also benefiting billions of people worldwide.
Valued at more than $130 million in 2009, the U.S. obesity drugs market is expected to grow at a healthy compound annual rate of 4.0%, with sales reaching nearly $160 million in 2014. Despite the conservatively modest 5-year forecast, a substantial number of novel drugs, including those indicated for type 2 diabetes, are being developed and studied for the treatment of obesity and may reach the market over the next decade, when the market is optimistically expected to expand exponentially. Among drugs pending FDA approval include Contrave, which received FDA panel recommendation for approval on December 7, 2010 and is expected to launch in the U.S. early 2011; as well as Qnexa and Lorqess, which are still pursuing FDA approval despite panel rejections, and may reach the market in 2011 or 2012-if the drugs are able to alleviate the FDA's concerns regarding drug safety. In addition, dozens of novel drugs are currently in Phase III clinical trials that may prove clinically safe and effective.
This dynamic report from Medtech Insight includes analyses of products, markets, competitors, and emerging technology and opportunities. Covered topics in this report include existing prescription weight loss drugs and emerging obesity drugs in preclinical or Phase I-III clinical trials including dozens of drugs under development for diabetes/metabolic disorders that are also being evaluated for the treatment of obesity; selected drugs being developed for targeted cellulite/fat reduction applications are also profiled.
EXECUTIVE SUMMARY i. Causes of Obesity a. Calorie Intake b. Genetics c. Behavior and Environment d. Diseases/Disorders and Drug Use ii. Health Risks a. Diabetes b. Cancer iii. Statistics iv. Obesity Drugs Market a. Market Forecast v. Methodology Exhibit ES-1: Body Mass Index and Obesity Exhibit ES-2: Surgeon General's Call to Action to Prevent and Decrease Overweight and Obesity Exhibit ES-3: Trends in Overweight, Obesity, and Morbid Obesity, 1988-2008 Exhibit ES-4: Trends in Overweight, Obesity, and Morbid Obesity, 1960-2008 Exhibit ES-5: Prescription Obesity Drugs, Market Forecast, 2009-2014 1. CLINICAL OVERVIEW OF OBESITY 1.1 Causes of Obesity 1.1.1 Calorie Intake 1.1.2 Genetics 1.1.3 Behavior and Environment 1.1.4 Diseases/Disorders and Drug Use 1.2 Health Risks 1.2.1 Diabetes 1.2.2 Cancer 1.3 Statistics Exhibit 1-1: Body Mass Index and Obesity Exhibit 1-2: Surgeon General's Call to Action to Prevent and Decrease Overweight and Obesity Exhibit 1-3: Comorbidities of Obesity Exhibit 1-4: Trends in Overweight, Obesity, and Morbid Obesity, 1988-2008 Exhibit 1-5: Trends in Overweight, Obesity, and Morbid Obesity, 1960-2008 Exhibit 1-6: Prevalence of Obesity Among Men, by Race/Ethnicity, 1988-1994 and 2007-2008 Exhibit 1-7: Prevalence of Obesity Among Women, by Race/Ethnicity, 1988-1994 and 2007-2008 Exhibit 1-8: 2007, Prevalence of Obesity Among Adults, by State 2. CURRENT AND EMERGING OBESITY DRUGS 2.1 Current Obesity/Weight Loss Drugs 2.1.1 Genentech/Roche Group with GlaxoSmithKline 2.1.2 Teva Pharmaceuticals/Teva Pharmaceutical Industries 2.2 Discontinued Obesity/Weight Loss Drugs 2.2.1 Abbott Laboratories 2.2.2 Merck 2.2.3 Pfizer 2.2.4 sanofi-aventis 2.3 Emerging Obesity/Weight Loss Drugs 2.3.1 Arena Pharmaceuticals with Eisai 2.3.2 Orexigen Therapeutics with Takeda Pharmaceutical 2.3.3 Vivus 2.4 Selected Obesity Drugs in Clinical Trials 2.4.1 7TM Pharma 2.4.2 Amylin Pharmaceuticals with Takeda Pharmaceutical 2.4.3 Compellis Pharmaceuticals 2.4.4 Emisphere Technologies 2.4.5 GlaxoSmithKline 2.4.6 Glenmark Pharmaceuticals 2.4.7 GW Pharmaceuticals 2.4.8 Lithera 2.4.9 Mitsubishi Tanabe Pharma/Mitsubishi with Johnson & Johnson 2.4.10 NeuroSearch 2.4.11 Norgine with Takeda Pharmaceuticals North America/ Takeda Pharmaceutical 2.4.12 Novo Nordisk 2.4.13 Obecure/Bio-Light 2.4.14 Phosphagenics with Calzada Limited 2.4.15 Roche Group with Ipsen 2.4.16 Shionogi 2.4.17 Transtech Pharma 2.4.18 Wyeth/Pfizer 2.4.19 Zealand Pharma with sanofi aventis 2.4.20 Zydus Cadila/Cadila Healthcare 2.5 Selected Obesity Drugs in Preclinical Development Exhibit 2-1: Selected Weight Loss Drugs and Their Adverse Effects, by Decade Exhibit 2-2: Orlistat, Mechanism of Action Exhibit 2-3: 2010, Emerging Obesity/Weight Loss Drugs Exhibit 2-4: 2010, Selected Obesity Drugs in Clinical Trials Exhibit 2-5: Lorcaserin, Selected BLOOM and BLOSSOM Clinical Trial Results Exhibit 2-6: SEQUEL Extension Trial, Primary Endpoints Exhibit 2-7: CP404, Mechanism of Action Exhibit 2-8: Tesofensine, Mechanism of Action Exhibit 2-9: 2010, Selected Obesity Drugs in Preclinical Development 3. OBESITY DRUGS MARKET 3.1 Market Analysis 3.1.1 Drugs Pending Approval 3.1.2 Emerging Drugs 3.1.3 Market Drivers 3.1.4 Market Limiters 3.2 Competitive Analysis Exhibit 3-1: Prescription Obesity Drugs, Market Forecast, 2009-2014 Exhibit 3-2: Prescription Obesity Drugs, Market Forecast, by Drug, 2009-2014 Exhibit 3-3: Selected Drugs under Development for the Treatment of Type 2 Diabetes and Obesity Exhibit 3-4: 2009, Prescription Obesity Drugs Market, Share by Supplier 4. COMPANY PROFILES 4.1 Amylin Pharmaceuticals, Inc. 4.2 Arena Pharmaceuticals, Inc. 4.3 Emisphere Technologies, Inc. 4.4 Genentech, Inc./Roche Group 4.5 NeuroSearch A/S 4.6 Norgine BV 4.7 Novo Nordisk A/S 4.8 Orexigen Therapeutics, Inc. 4.9 Shionogi & Co. LTD 4.10 Takeda Pharmaceutical Company Limited 4.11 Vivus, Inc. 4.12 Zealand Pharma A/S APPENDIX: COMPANY LISTING